Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Blockade of the renin–angiotensin–aldosterone system is a therapeutic mainstay in patients with chronic kidney disease (CKD). However, the renoprotective effect of the novel direct renin inhibitor aliskiren is unknown.
Materials and methods
We performed a prospective study in 10 CKD patients. All 10 patients with persistent proteinuria (urinary protein-to-creatinin ratio 0.3–3.5 g/g), despite good blood pressure control (<130/80 mmHg) with olmesartan, were started on 150 mg/day aliskiren. Clinical parameters were examined before and after 4, 8, 12, and 16 weeks of treatment.
Urinary protein-to-creatinine ratio significantly decreased by about 40% at 16 weeks from baseline (P = 0.0002), although estimated glomerular filtration rate and blood pressure did not change throughout the study period. Plasma renin activity also decreased significantly from baseline (P = 0.019), although plasma aldosterone concentration did not change.
Aliskiren combined with olmesartan reduces proteinuria in CKD patients.
- Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease
International Urology and Nephrology
Volume 44, Issue 3 , pp 841-845
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Chronic kidney disease
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine, Kidney Center, Tokyo Women’s Medical University, Kawada-cho 8-1, Shinjyuku-ku, Tokyo, 162-8666, Japan